Sweden's news in English

Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland

Swedes buy US cancer research firm

Share this article

Swedes buy US cancer research firm
00:35 CEST+02:00
AstraZeneca said on Tuesday that it has agreed to buy US-based cancer drugs company Amplimmune, as the Anglo-Swedish pharmaceuticals group seeks to bolster its flagging pipeline of new products.

Under the deal, MedImmune will acquire 100 percent of Amplimmune's shares for an initial price of $225 million, with another $275 million deferred until it reaches key drug-development milestones.to fight cancer will be complemented by Amplimmune's innovative work in this area," said Bahija Jallal, executive vice president of MedImmune. "It will allow us to strengthen our arsenal of potential cancer therapies.

"We are excited to be working with the Amplimmune team to help find new treatments to address areas of unmet medical need."

"AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology," a statement said.

"MedImmune's focus on harnessing the power of the patient's own immune system

Amplimmune is AstraZeneca's latest acquisition under new chief executive Pascal Soriot, who joined in October last year. The London-listed group purchased US firm Pearl Therapeutics in June for up to $1.15 billion.

AFP/The Local/at

Follow The Local on Twitter

 
Get notified about breaking news on The Local

Share this article

The Local is not responsible for content posted by users.
Become a Member or sign-in to leave a comment.

From our sponsors

How to work 9-5 and travel the rest of the time

A full-time job shouldn't stop you from satisfying your wanderlust. The Local spoke to Travel After 5 blogger Alline Waldhelm to find out her tips and tricks for travellers who only have 25 days of annual leave.

Discussion forum